Kura Oncology (KURA) Cash from Financing Activities (2010 - 2026)

Kura Oncology (KURA) has 15 years of Cash from Financing Activities data on file, last reported at $69000.0 in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $69000.0, down 51.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (down 72.23% YoY), and the FY2025 annual result was $1.8 million, down 98.84% from the prior year.
• Cash from Financing Activities declined to $69000.0 in Q1 2026 per KURA's latest filing, from $1.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $148.4 million in Q1 2024 and troughed at $69000.0 in Q1 2026.
• A 5-year average of $14.0 million and a median of $843000.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities surged 4271.91% in 2022, then tumbled 99.9% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $34.7 million in 2022, then sank by 98.01% to $691000.0 in 2023, then climbed by 16.64% to $806000.0 in 2024, then jumped by 40.82% to $1.1 million in 2025, then slumped by 93.92% to $69000.0 in 2026.
• Business Quant data shows KURA's Cash from Financing Activities at $69000.0 in Q1 2026, $1.1 million in Q4 2025, and $515000.0 in Q2 2025.